Literature DB >> 1757727

Perspectives of CCK antagonists in pancreatic research. Part II. Experimental studies.

T Takács1, A Pap.   

Abstract

In this article, the effects of different classes of cholecystokinin (CCK) receptor antagonists in CCK-related physiological processes of the pancreas have been discussed. Both glutaramic acid derivatives and natural (benzodiazepine) analogs are potent, competitive antagonists of peripheral CCK receptors. These compounds thus provide a powerful tool for investigating the physiological and pharmacological actions of CCK in the gastrointestinal system, and have already clarified the role of CCK in pancreatic secretion and trophism or growth.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1757727     DOI： 10.1007/bf02924248

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN： 0169-4197


  47 in total

1.  Actions of derivatives of cyclic nucleotides on dispersed acini from guinea pig pancreas. Discovery of a competitive antagonist of the action of cholecystokinin.

Authors:  S R Peikin; C L Costenbader; J D Gardner
Journal:  J Biol Chem       Date:  1979-06-25       Impact factor: 5.157

2.  Effects of L-364,718, a new cholecystokinin receptor antagonist, on camostate-induced growth of the rat pancreas.

Authors:  J R Wisner; R E McLaughlin; K A Rich; S Ozawa; I G Renner
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

3.  Effect of CCK antagonist L 364718 on meal-induced pancreatic secretion in rats.

Authors:  M F O'Rourke; R D Reidelberger; T E Solomon
Journal:  Am J Physiol       Date:  1990-02

4.  Brain CCK receptors are structurally distinct from pancreas CCK receptors.

Authors:  C Sakamoto; J A Williams; I D Goldfine
Journal:  Biochem Biophys Res Commun       Date:  1984-10-30       Impact factor: 3.575

5.  Differentiation of central and peripheral cholecystokinin receptors by new glutaramic acid derivatives with cholecystokinin-antagonistic activity.

Authors:  F Makovec; M Bani; R Chisté; L Revel; L C Rovati; L A Rovati
Journal:  Arzneimittelforschung       Date:  1986

6.  Selective inhibition of pentagastrin- and cholecystokinin-stimulated exocrine secretion by proglumide.

Authors:  C J Loewe; J R Grider; J Gardiner; Z R Vlahcevic
Journal:  Gastroenterology       Date:  1985-10       Impact factor: 22.682

7.  Hormonal control of pancreatic growth.

Authors:  D L Mainz; O Black; P D Webster
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

8.  The cholecystokinin receptor antagonist CR1409 increases plasma cholecystokinin in rats.

Authors:  J B Jansen; A J de Jong; C B Lamers
Journal:  Regul Pept       Date:  1989-02

9.  Short-term inhibition of duodenal tryptic activity does not affect human pancreatic, biliary, or gastric function.

Authors:  J Hotz; S B Ho; V L Go; E P DiMagno
Journal:  J Lab Clin Med       Date:  1983-03

10.  Cholecystokinin mediates feedback regulation of pancreatic enzyme secretion in rats.

Authors:  D S Louie; D May; P Miller; C Owyang
Journal:  Am J Physiol       Date:  1986-02
View more
  3 in total

1.  Effect of chronic oral administration of the CCK receptor antagonist loxiglumide on exocrine and endocrine pancreas in normal rats.

Authors:  I Imoto; M Yamamoto; D M Jia; M Otsuki
Journal:  Int J Pancreatol       Date:  1997-12

2.  Duration of anti-cholecystokinin (CCK) action on the rat exocrine pancreas of new CCK receptor antagonist FK480 administered orally.

Authors:  Y Moriyoshi; K Shiratori; C Iwabe; S Watanabe; T Takeuchi
Journal:  J Gastroenterol       Date:  1996-04       Impact factor: 7.527

3.  Duration and potency of anticholecystokinin action of subcutaneous and oral loxiglumide on cerulein-stimulated pancreatic exocrine secretion.

Authors:  N Watanabe; M Otsuki
Journal:  Int J Pancreatol       Date:  1993-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.